T0	Participants 60 113	patients with unresectable HCC and in HCC cell lines.
T1	Participants 259 271	HCC patients
T2	Participants 342 403	HCC patients who had both elevated AFP and DCP were included.
T3	Participants 491 517	27-patient phase II cohort